Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Coronary Artery Disease
Interventions: Cardiac PET, Coronary catheterization; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 100 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Tay-Sachs Disease, Sandhoff Disease
Interventions: AXO-AAV-GM2 Starting Dose, AXO-AAV-GM2 Low Dose, AXO-AAV-GM2 Middle Dose, AXO-AAV-GM2 High Dose; Biological
Lead sponsor: Terence Flotte; Other
Eligibility: 6 Months to 12 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Worcester, Massachusetts

Conditions: Breast Cancer
Interventions: gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment; Genetic · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 20 Years and older · Female only
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 3
States / cities: Beverly Hills, California • Duarte, California • Pasadena, California

Conditions: Multiple Sclerosis, Healthy
Interventions: thoracic duct cannulation; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Telemedicine, Control; Other
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Nicotine, E-liquid Flavors
Interventions: Nicotine 0 mg/mL, Nicotine 6 mg/mL, Nicotine 12 mg/mL, Nicotine 24 mg/mL, 'Menthol' flavor, 'Menthol/Mint' flavor, 'Green Apple' flavor, 'Watermelon' flavor, 'Unflavored'; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions: Cefazolin, Silberg Tissue Preparation System; Drug · Device
Lead sponsor: Sonescence, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Sebastopol, California

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more

Conditions: COVID
Interventions: CRI; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Anemia, Iron-deficiency
Interventions: Ferric Maltol, Ferrous sulfate; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Saraland, Alabama • Homestead, Florida • Kissimmee, Florida + 10 more

Conditions: Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions: citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy; Drug · Genetic · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Microstomia, Scleroderma
Interventions: Hyaluronidase, CO2 laser; Drug · Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Shoulder Arthropathy Associated With Other Conditions, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Pain
Interventions: Jumpstart Dressing, Standard Dressing; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Abdominal Surgery, Hysterectomy, Genital Prolapse
Interventions: Esophageal probe; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Vascular Closure, Electrophysiology Study
Interventions: MYNX CONTROLTM VENOUS Vascular Closure Device; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: Not listed
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more

Conditions: Asthma
Interventions: MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more

Conditions: Labor Complication
Interventions: Continue Oxytocin, Discontinue Oxytocin; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Ketoacidosis
Interventions: Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion; Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Schizophrenia
Interventions: D-serine; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York

Conditions: Healthy, Maxillary First Premolar Tooth Extraction, Canine Retraction
Interventions: Tooth movement; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 11 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: aflibercept; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Bladder Cancer (BC), Transurethral Resection of Bladdertumors, Transurethral Resection of the Bladder, Non-Muscle Invasive Bladder Carcinoma
Interventions: HISA; Device
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: KRAS P.G12C
Interventions: FoundationOne® Liquid CDx; Diagnostic Test
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

Telemedicine for Adolescents With Insulin-dependent Diabetes

Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Compensatory Reserve Index (CRI) for Management of COVID-19

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Microcurrent Dressing to Treat Infections, Before, During and After Surgery

Intraoperative Goal-directed Fluid Management

Mobilization and Outcomes After Venous Closure

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

The Role of Oxytocin in the Second Stage of Labor

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

COMbination of Bipolar Androgen Therapy and Nivolumab

Safety and Effectiveness of D-serine in Schizophrenia

Gingival Crevicular Fluid Characterization During Orthodontic Treatment

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

Feasibility of HISA During TURBT for NMIBC

Studying Pathways of Resistance in KRAS-driven Cancers